Opendata, web and dolomites

TherVacB SIGNED

THERVACB: A THERAPEUTIC VACCINE TO CURE HEPATITIS B

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TherVacB project word cloud

Explore the words cloud of the TherVacB project. It provides you a very rough idea of what is the project "TherVacB" about.

interaction    preclinical    safety    approved    clinically    therapy    scheme    interdisciplinary    therapeutic    cell    prime    heterologous    immune    clinical    human    breaking    center    carries    burden    worldwide    tend    immunity    track    efficacy    inducing    biomarkers    treatment    stigmatize    ib    realized    virology    occurrence    options    expressing    neutralizing    media    mva    perform    tackle    iia    secured    monitoring    first    ethical    hepatitis    protected    boost    host    resistance    antibodies    tolerance    innovative    diagnostic    induce    antigens    vector    hbv    gmp    local    patients    capacity    lacking    polymerase    experts    immunology    protein    proof    care    thervacb    ip    jointly    form    vaccine    cells    proving    translational    lacks    core    cure    obtain    social    trial    prepare    of    injections    infectious    vaccination    chronic    quantify    activate    components    recruitment    arm    registry    boosted    africa    tanzania    excellent    resolution    spontaneous    found    gt    record    models    adjuvanted    diseases    empirical    particulate    predict    patient    95    infection    virus    proven   

Project "TherVacB" data sheet

The following table provides information about the project.

Coordinator
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH 

Organization address
address: INGOLSTADTER LANDSTRASSE 1
city: NEUHERBERG
postcode: 85764
website: www.helmholtz-muenchen.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 10˙425˙686 €
 EC max contribution 10˙425˙686 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2019-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH DE (NEUHERBERG) coordinator 4˙049˙761.00
2    KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN DE (MUENCHEN) participant 1˙394˙787.00
3    CTC NORTH GMBH & CO KG DE (HAMBURG) participant 1˙113˙125.00
4    AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA IT (PARMA) participant 714˙893.00
5    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 675˙380.00
6    UNIVERSITY COLLEGE LONDON UK (LONDON) participant 536˙023.00
7    NATIONAL INSTITUTE FOR MEDICAL RESEARCH TZ (DAR ES SALAAM) participant 489˙287.00
8    ARTTIC FR (PARIS) participant 272˙746.00
9    UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF DE (HAMBURG) participant 209˙350.00
10    TECHNISCHE UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 191˙556.00
11    FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA ES (BARCELONA) participant 153˙750.00
12    HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH DE (BRAUNSCHWEIG) participant 146˙500.00
13    UNIVERSITAET LEIPZIG DE (LEIPZIG) participant 142˙900.00
14    MEDIZINISCHE HOCHSCHULE HANNOVER DE (HANNOVER) participant 131˙125.00
15    BARTS AND THE LONDON NHS TRUST UK (LONDON) participant 104˙500.00
16    ROYAL FREE LONDON NHS FOUNDATION TRUST UK (LONDON) participant 100˙000.00

Map

 Project objective

Experts in virology, immunology and clinical hepatitis B patient care with an excellent research and translational track record in hepatitis B virus (HBV)-host interaction form the interdisciplinary TherVacB consortium. They jointly tackle the major challenges in HBV therapy – the virus’s resistance to cure. TherVacB aims at breaking immune tolerance in chronic HBV infection and achieving HBV cure. Occurrence of neutralizing antibodies and HBV-specific T cell responses characterize spontaneous resolution of HBV infection that are lacking in chronic infection. We will use our IP-protected heterologous prime-boost therapeutic vaccination scheme with proven efficacy in preclinical models of hepatitis B to target and activate B and T cell responses. Two protein prime injections with clinically approved, adjuvanted particulate HBV S and core protein antigens shall induce neutralizing antibodies and prime T cells that are boosted with an MVA vector expressing HBV core, S, L and polymerase antigens covering >95% of HBV found worldwide. Having secured significant funding and partnerships to obtain GMP-produced vaccine components and to prepare a first-in-human application, TherVacB aims at a clinical proof-of-concept of the therapeutic hepatitis B vaccine in patients with chronic hepatitis B. The consortium will establish a patient registry and perform a multi-center phase Ib/IIa clinical trial that aims at proving safety of the therapeutic vaccine and inducing immune control of chronic HBV infection. One study arm will be realized in Tanzania to build up local capacity, because Africa carries a large burden of HBV infection but lacks diagnostic and therapeutic options. An innovative immune monitoring will quantify HBV-specific immunity and define novel biomarkers to predict treatment response. Finally an ethical and an empirical study will evaluate the recruitment of patients by social media which is very effective for infectious diseases that tend to stigmatize patients

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERVACB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THERVACB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More